Crinetics Pharmaceuticals, Inc. Stockholders Equity

Quick Answer

Crinetics Pharmaceuticals, Inc. reported Stockholders Equity of $992.08 million for fiscal year 2025.

Crinetics Pharmaceuticals, Inc. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 $992.08M -25.1%
2024 $1.32B +145.7%
2023 $539.11M +70.4%
2022 $316.33M -4.7%
2021 $331.94M +96.5%
2020 $168.92M +44.2%
2019 $117.14M -26.9%
2018 $160.22M +1166.6%
2017 -$15.02M -142.1%
2016 -$6.20M -1240.0%
2015 -$463.0K

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 $1.07B +28.7% -8.5%
June 30, 2025 $1.17B +41.0% -6.6%
March 31, 2025 $1.25B +43.3% -5.3%
December 31, 2024 $1.32B +145.7% +59.0%
September 30, 2024 $832.98M +52.1% +0.3%
June 30, 2024 $830.76M +226.9% -5.0%
March 31, 2024 $874.93M +212.1% +62.3%
December 31, 2023 $539.11M +70.4% -1.6%
  • Crinetics Pharmaceuticals, Inc. showed a decrease of -25.1% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2015–2025 period, Crinetics Pharmaceuticals, Inc.’s stockholders equity has grown by 214372.8% (from -$463.0 thousand to $992.08 million).
  • The most recent figure is from Crinetics Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment